Wells Fargo has made notable revisions to its price targets, raising Sandisk's from $380 to $675 while simultaneously reducing Apellis Pharmaceuticals' to $26, all within a context of preparing for a pivotal 2026. The bank expects strong net interest income growth and is targeting up to $10 billion in cost cuts, despite slightly lagging behind analysts' expectations in revenue performance. As it navigates regulatory changes, Wells Fargo aims to enhance operational efficiency and leverage tech partnerships for future growth.
“Companies including JPMorgan Chase, Wells Fargo, and Bank of America Corporation · have shown interest in · being involved in rollover accounts · true”
“BofA and Wells Fargo · raised · price target on Sandisk · $675 from $380”
“Wells Fargo · reduced · price target for Apellis Pharmaceuticals Inc. · to $26 from $29”
“Wells Fargo · maintained · an Overweight rating · for Apellis Pharmaceuticals Inc.”
“Wells Fargo · cited · a slower-than-anticipated commercial ramp for Empaveli · in C3G and IC-MPGN indications”
“Well Fargo · raised · price target on Sandisk · to $675 from $380”
“Wells Fargo · lowered the price target for AT&T · $27 · from $29”
“Wells Fargo · maintained an · Overweight rating”
“Wells Fargo · raised · price target on Sandisk · to $675 from $380”
“Wells Fargo · declared dividend · $0.45 · January 27”
“Wells Fargo · initiated coverage of · Heartflow · Overweight rating and $38 price target”
“Wells Fargo & Co. · volume · stock · 1,555,701”
